

# Vincenzo Di Noia

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8143184/vincenzo-di-noia-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

345  
citations

12  
h-index

17  
g-index

34  
ext. papers

546  
ext. citations

4.4  
avg, IF

3.29  
L-index

#	Paper	IF	Citations
32	Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!. <i>European Journal of Cancer</i> , <b>2022</b> , 165, 169-173	7.5	2
31	Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	14
30	The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 260-264	7.5	20
29	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1583-1592	7.4	4
28	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2021</b> , 152, 1-6	5.9	3
27	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 880-889	3.2	13
26	PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 351-360	4.9	2
25	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	1
24	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 164, 103404	7	6
23	Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 253-254	7.5	1
22	Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	14
21	Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?. <i>Lung Cancer</i> , <b>2020</b> , 145, 208-210	5.9	9
20	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$ . <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 2209-2221	7.4	32
19	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	27
18	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 498-508.e2	4.9	27
17	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$ : a multicenter study with external validation <b>2020</b> , 8,		29
16	Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?". <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 23	5.4	3

15	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 3775-3782	3.6	4
14	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 7652014	4.3	21
13	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 921-930	3.8	5
12	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 82-87	4.9	11
11	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , <b>2019</b> , 25, 513-520	2.6	4
10	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 2349-2360	3.6	7
9	Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?. <i>Future Oncology</i> , <b>2018</b> , 14, 919-926	3.6	16
8	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 937-945	5.4	10
7	The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the Unexplainable. <i>Personalized Medicine</i> , <b>2018</b> , 15, 319-327	2.2	1
6	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. <i>Molecular Diagnosis and Therapy</i> , <b>2018</b> , 22, 723-728	4.5	8
5	Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, E4-E9	2.8	
4	Transradial versus Transfemoral Access for Hepatic Chemoembolization: Inpatient Prospective Single-Center Study. <i>Journal of Vascular and Interventional Radiology</i> , <b>2017</b> , 28, 1234-1239	2.4	29
3	Are TKIs favourable for the elderly with non-small-cell lung cancer?. <i>Oncotarget</i> , <b>2016</b> , 7, 46871-46877	3.3	6
2	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 599-609	4.4	15
1	DEBIRI and capecitabine in refractory prevalently liver metastases of colorectal cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 724-724	2.2	